However, with the emergence of ibrutinib resistance, and CLL cases expressing high levels of the adhesion molecule, CD49d, typically failing to display ibrutinib-induced lymphocytosis, there is an urgent need to develop new combination therapies for these subsets of patients [23]. The gene discussed is ITGA4; the disease is B-cell chronic lymphocytic leukemia.